Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
40.74
+0.87 (2.18%)
At close: Aug 13, 2025, 4:00 PM
40.73
-0.01 (-0.02%)
After-hours: Aug 13, 2025, 4:20 PM EDT
Kymera Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Cash & Equivalents | 335.82 | 120.26 | 109.97 | 68.4 | 47.98 | 31 | Upgrade
|
| Short-Term Investments | 329.63 | 368.49 | 264.92 | 338.77 | 394.44 | 265.2 | Upgrade
|
| Cash & Short-Term Investments | 665.45 | 488.74 | 374.88 | 407.17 | 442.42 | 296.2 | Upgrade
|
| Cash Growth | 30.49% | 30.37% | -7.93% | -7.97% | 49.36% | 222.11% | Upgrade
|
| Accounts Receivable | 40 | 0.95 | 18.76 | 2.54 | 0.14 | 1.43 | Upgrade
|
| Receivables | 40 | 0.95 | 18.76 | 2.54 | 0.14 | 1.43 | Upgrade
|
| Prepaid Expenses | 22.88 | 20.58 | 11.67 | 9.71 | 8.72 | 4.7 | Upgrade
|
| Total Current Assets | 728.33 | 510.27 | 405.32 | 419.42 | 451.27 | 302.34 | Upgrade
|
| Property, Plant & Equipment | 94.62 | 97.86 | 101.08 | 22.24 | 21.31 | 20.69 | Upgrade
|
| Long-Term Investments | 297.63 | 362.16 | 61.43 | 152.33 | 125.19 | 162.53 | Upgrade
|
| Other Long-Term Assets | 10.5 | 7.74 | 7.93 | 9.15 | 8.14 | 1.62 | Upgrade
|
| Total Assets | 1,131 | 978.04 | 575.76 | 603.13 | 605.91 | 487.18 | Upgrade
|
| Accounts Payable | 5.78 | 5.99 | 7.08 | 4.34 | 4.01 | 4.37 | Upgrade
|
| Accrued Expenses | 27.98 | 34.87 | 33.86 | 27.5 | 22.97 | 10.33 | Upgrade
|
| Current Portion of Leases | 13.67 | 13.11 | 6.35 | 3.94 | 3.6 | 3.26 | Upgrade
|
| Current Unearned Revenue | 40 | 13.58 | 37.88 | 35.26 | 61.74 | 92.55 | Upgrade
|
| Other Current Liabilities | 0.12 | 0.22 | 0.52 | 0.3 | 0.23 | 0.11 | Upgrade
|
| Total Current Liabilities | 87.54 | 67.77 | 85.69 | 71.34 | 92.54 | 110.62 | Upgrade
|
| Long-Term Leases | 72.05 | 74.65 | 78.33 | 13.39 | 14.36 | 14.73 | Upgrade
|
| Long-Term Unearned Revenue | - | - | 16.77 | 28 | 39.3 | 77.84 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | 0.25 | 0.07 | 0.1 | Upgrade
|
| Total Liabilities | 159.59 | 142.42 | 180.79 | 112.98 | 146.27 | 203.29 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| Additional Paid-In Capital | 1,868 | 1,592 | 926.27 | 878.88 | 689.28 | 412.78 | Upgrade
|
| Retained Earnings | -896.81 | -754.61 | -530.75 | -383.79 | -228.98 | -128.77 | Upgrade
|
| Comprehensive Income & Other | 0.28 | -1.49 | -0.55 | -4.95 | -0.66 | -0.13 | Upgrade
|
| Total Common Equity | 971.48 | 835.62 | 394.97 | 490.15 | 459.64 | 283.89 | Upgrade
|
| Shareholders' Equity | 971.48 | 835.62 | 394.97 | 490.15 | 459.64 | 283.89 | Upgrade
|
| Total Liabilities & Equity | 1,131 | 978.04 | 575.76 | 603.13 | 605.91 | 487.18 | Upgrade
|
| Total Debt | 85.71 | 87.76 | 84.67 | 17.34 | 17.96 | 17.99 | Upgrade
|
| Net Cash (Debt) | 877.36 | 763.14 | 351.64 | 542.16 | 549.64 | 440.74 | Upgrade
|
| Net Cash Growth | 42.84% | 117.02% | -35.14% | -1.36% | 24.71% | 522.83% | Upgrade
|
| Net Cash Per Share | 11.07 | 10.17 | 6.02 | 10.05 | 11.45 | 25.40 | Upgrade
|
| Filing Date Shares Outstanding | 71.5 | 64.94 | 61.11 | 55.18 | 51.67 | 44.81 | Upgrade
|
| Total Common Shares Outstanding | 70.56 | 64.89 | 55.59 | 55.04 | 51.5 | 44.48 | Upgrade
|
| Working Capital | 640.79 | 442.5 | 319.63 | 348.07 | 358.73 | 191.72 | Upgrade
|
| Book Value Per Share | 13.77 | 12.88 | 7.11 | 8.91 | 8.93 | 6.38 | Upgrade
|
| Tangible Book Value | 971.48 | 835.62 | 394.97 | 490.15 | 459.64 | 283.89 | Upgrade
|
| Tangible Book Value Per Share | 13.77 | 12.88 | 7.11 | 8.91 | 8.93 | 6.38 | Upgrade
|
| Machinery | 15.79 | 14.75 | 6.74 | 5.8 | 4.02 | 2.59 | Upgrade
|
| Leasehold Improvements | 44.17 | 44.01 | 7.8 | 7.8 | 7.74 | 7.6 | Upgrade
|
Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.